BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Choi YI, Chung JW, Park DK, Kim KO, Kwon KA, Kim YJ, Seo JY. Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: A comparative, open trial. World J Gastroenterol 2019; 25(46): 6743-6751 [PMID: 31857776 DOI: 10.3748/wjg.v25.i46.6743]
URL: https://www.wjgnet.com/1007-9327/full/v25/i46/6743.htm
Number Citing Articles
1
Francis Megraud, Robin Bruyndonckx, Samuel Coenen, Linda Wittkop, Te-Din Huang, Martin Hoebeke, Lucie Bénéjat, Philippe Lehours, Herman Goossens, Youri Glupczynski. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the communityGut 2021; 70(10): 1815 doi: 10.1136/gutjnl-2021-324032
2
Yu Huang, Jinnan Chen, Zhaohui Ding, Xiao Liang, Hong Lu. Susceptibility testing alone will not reliably achieve high Helicobacter pylori cure rates: A systematic review and meta‐analysis Journal of Gastroenterology and Hepatology 2022;  doi: 10.1111/jgh.15864
3
Biao Guo, Nv-Wei Cao, Hao-Yue Zhou, Xiu-Jie Chu, Bao-Zhu Li. Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysisMicrobial Pathogenesis 2021; 152: 104661 doi: 10.1016/j.micpath.2020.104661
4
Anthony O'Connor, Takahisa Furuta, Javier P. Gisbert, Colm O'Morain. Review – Treatment of Helicobacter pylori infection 2020 Helicobacter 2020; 25(S1) doi: 10.1111/hel.12743
5
Jun-Hyung Cho, So-Young Jin. Current guidelines for <i>Helicobacter pylori </i>treatment in East Asia 2022: Differences among China, Japan, and South KoreaWorld Journal of Clinical Cases 2022; 10(19): 6349-6359 doi: 10.12998/wjcc.v10.i19.6349
6
Caiqi Liu, Yuan Wang, Jiaqi Shi, Chunhui Zhang, Jianhua Nie, Shun Li, Tongsen Zheng. The status and progress of first-line treatment against Helicobacter pylori infection: a reviewTherapeutic Advances in Gastroenterology 2021; 14: 175628482198917 doi: 10.1177/1756284821989177
7
Hyungchul Park, Jeong Hoon Lee. Recent Trends in Tailored Treatments for Helicobacter pylori InfectionThe Korean Journal of Helicobacter and Upper Gastrointestinal Research 2021; 21(2): 115 doi: 10.7704/kjhugr.2021.0005
8
Youn I Choi, Jun-Won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim, Jung Ho Kim, Ja Young Seo, Dong Kyun Park. Tailored eradication strategy <i>vs</i> concomitant therapy for <i>Helicobacter pylori</i> eradication treatment in Korean patientsWorld Journal of Gastroenterology 2021; 27(31): 5247-5258 doi: 10.3748/wjg.v27.i31.5247
9
Jun-Hyung Cho, So Young Jin, Suyeon Park. Comparison of tailored Helicobacter pylori eradication versus modified bismuth quadruple therapy in Korea: a randomized controlled trialExpert Review of Anti-infective Therapy 2022; 20(6): 923 doi: 10.1080/14787210.2022.2017280
10
Olga P. Nyssen, Marta Espada, Javier P. Gisbert. Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-AnalysisFrontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.913436
11
A Reum Choe, Ki-Nam Shim, Yehyun Park, Eun-Mi Song, Chung Hyun Tae, Sung-Ae Jung. Cost-Effectiveness, Efficacy, and Safety Analysis of Tailored Therapy in Patients with Helicobacter pylori InfectionJournal of Clinical Medicine 2021; 10(12): 2619 doi: 10.3390/jcm10122619
12
Javier P. Gisbert. Empirical or susceptibility-guided treatment forHelicobacter pyloriinfection? A comprehensive reviewTherapeutic Advances in Gastroenterology 2020; 13: 175628482096873 doi: 10.1177/1756284820968736
13
Erick A. Argueta, Steven F. Moss. Management of Helicobacter pyloriCurrent Opinion in Gastroenterology 2020; 36(6): 518 doi: 10.1097/MOG.0000000000000678
14
Sang Yoon Kim, Jae Myung Park, Chul-Hyun Lim, Hye Ah Lee, Ga-Yeong Shin, Younghee Choe, Yu Kyung Cho, Myung-Gyu Choi. Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for Helicobacter pyloriGut and Liver 2021; 15(4): 528 doi: 10.5009/gnl20225